Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers September 19, 2017
Pharmacy Choice - News - Pharmaceutical Development - September 19, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/12/17 - AbbVie stirs safety jitters after two patients die in ABT-494 study [Arab Finance (Egypt)]
AbbVie$ ABBV revealed that two rheumatoid arthritis patients died in its late-stage work on ABT-494, which quickly triggered a case of the jitters for a drug touted as a major part of the companys late-stage pipeline hopes. AbbVie had focused hard on the positive efficacy data for this drug, now through two Phase III trials. Just a few days ago Abb
AC Immune completes Recruitment for Low-Dose Cohort of Participants in World's First Clinical Trial for anti-Abeta Vaccine Targeting Alzheimer's Disease-like Characteristics in Individuals with Down Syndrome. Phase 1 b study of AC Immune's ACI-24, the first anti-amyloid vaccine for treatment of Alzheimer's disease-like characteristics in...
9/12/17 - Aldeyra Therapeutics Announces Positive Results from Dry Eye Disease Phase 2a Clinical Trial
Aldeyra Therapeutics, Inc., a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced positive results from a Phase 2 a clinical trial of topical ocular ADX-102 in patients with dry eye disease. "ADX-102 is a promising agent fo
9/12/17 - American Gene Technologies Inc. Appoints Julia R. Brown to its Board of Directors [Namibian Sun]
-American Gene Technologies International Inc., a leading gene and cell therapy company with a broad and robust lentiviral drug-development platform, today announced the appointment of Julia R. Brown to its board of directors. Ms. Brown has extensive experience in development stage pharmaceutical/biopharmaceutical and commercial stage specialty...
9/12/17 - Cancer Patients Struggle to Understand Clinical Trials [Sport360]
Cancer patients struggle to understand what is involved in a clinical trial, even when they have participated in them. The survey involved 1090 patients who were attending 14 cancer centers in Ireland. "This shows poor understanding of randomization, and we know this is a difficult concept for patients," commented lead author Catherine Kelly, MD,
9/12/17 - Cardiome Announces Agreement with Basilea for Distribution of Zevtera/Mabelio (Ceftobiprole) in Europe and Israel
-Cardiome Pharma Corp. today announced that it has entered into a distribution and license agreement with Basilea for its antibiotic Zevtera / Mabelio . Under the terms of the agreement, Basilea has granted Cardiome an exclusive license to commercialize ceftobiprole in 34 European countries and Israel. The drug is currently marketed in Germany,
9/12/17 - Cardiome Announces Agreement with Basilea for Distribution of Zevtera/Mabelio (Ceftobiprole) in Europe and Israel
-Cardiome Pharma Corp. today announced that it has entered into a distribution and license agreement with Basilea for its antibiotic Zevtera / Mabelio . Under the terms of the agreement, Basilea has granted Cardiome an exclusive license to commercialize ceftobiprole in 34 European countries and Israel. The drug is currently marketed in Germany,
9/12/17 - Checkpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer [All Iraq News Agency (AIN)]
Checkpoint Therapeutics, Inc., a Fortress Biotech company, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to CK-101, the Companys third-generation epidermal growth-factor receptor inhibitor, for the treatment of EGFR mutation-positive non-small cell lung cancer. Orphan Drug Designation is granted by t
9/12/17 - Chi-Med Initiates a Phase I Clinical Trial of Selective PI3Kd Inhibitor HMPL-689 in Lymphoma Patients in China
By a News Reporter-Staff News Editor at China Weekly News Hutchison China MediTech Limited has initiated a Phase I clinical trial of HMPL-689 in China. HMPL-689 is a novel, highly selective and potent small molecule inhibitor targeting phosphoinositide-3 kinase delta isoform, a key component in the B-cell receptor signaling pathway.
9/12/17 - Combine Solicitation - 68 FY18 Radio pharmacy
Office Address: Department of Veterans Affairs; Network Contracting Office 4; WVAMC Wilmington VA Medical Center; 1601 Kirkwood Highway; Wilmington, DE 19805. Description: Department of Veterans Affairs. The Wilmington, Delaware VA Medical Center has a procurement request for radiopharmaceuticals.
9/12/17 - Coronary Stents Market: Pit Falls, Present Scenario and Growth Prospects from 2017 to 2025
San Francisco, CA 09/11/2017 Global Coronary Stents Market: OverviewCoronary stents are used during the treatment of coronary arteries that supply the heart muscle with blood. A tube-shaped device inserted in coronary arteries, they help open up an artery and are left there permanently.Fat often gets deposited along the arterial wall, thereby
9/12/17 - Demand for DrugDev Spark? Soars Among Small Biotechs and Pharma Seeking Best-in-Class Technology for Clinical Trial Planning, Startup and Conduct
DrugDev, a QuintilesIMS company, continues to strengthen its position as the clinical technology provider for small to mid-size biotechs and pharma worldwide with continued adoption of the DrugDev Spark? unified clinical trial suite. DrugDev's growth has come as a result of proven success improving clinical trials across therapeutic areas with sp
9/12/17 - Easton Pharmaceuticals Announces That Its Partner Windsor Pharmaceuticals Has Received Regulatory Approvals For Products VS-Sense and AL-Sense For Central America and The Caribbean
Easton Pharmaceuticals Inc. and its JV partner BMV Medica SA de CV announces that its distributor Windsor Pharmaceuticals SA has received regulatory approval for two of its exclusively licensed Women's Health Care products for Central America and the Caribbean. After filing the regulatory documents subsequent to a signed sub-licensing agreement wit
9/12/17 - ERYTECH to Present at Morgan Stanley Global Healthcare Conference
ERYTECH Pharma, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen, Chairman and Chief Executive Officer, will present at the 15 th Annual Morgan Stanley Global Healthcare Conference on September 13th, 2017 at the Grand Hyatt.
9/12/17 - Expensive Drug Driving Up Medicare Expenditures Without Evidence of Greater Efficacy
Oregon Health and Science University issued the following news release:. Medicare spent more than $1 billion over a five-year period and more than $500 million in 2015 alone on a high-priced drug that has not proved more effective than much less expensive corticosteroids, researchers at OHSU in Portland, Oregon, and the OHSU/Oregon State University
9/12/17 - FDA Acknowledges Receipt Of Sorrento Therapeutics Inc, NDA For ZTlido?; PDUFA Date Set For February 28, 2018
Sorrento Therapeutics, Inc., announced today that SCILEX Pharmaceuticals Inc., a majority-owned subsidiary of Sorrento, has received from the U.S. Food and Drug Administration acknowledgement of receipt of its recently resubmitted New Drug Application for ZTlido? which has been considered a complete, class 2 response to the prior action letter.
9/12/17 - Featured Company News - Teva Pharmaceuticals Presents Outcome Measure Results from Phase-III Clinical Trials for the Potential of Fremanezumab to Treat Migraine Patients
LONDON, UK/ ACCESSWIRE/ September 12, 2017/ Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Teva Pharmaceutical Industries Ltd., following which we have published a free report that can be viewed by signing up at The Company announced on September 9, 2017 the late-brea
9/12/17 - Glenmark gets USFDA approval for Rythmol SR generic [Algeria Press Service]
Glenmark Pharmaceuticals has received final approval from the US health regulator for generic version of Rythmol SR capsules, an anti-arrhythmic medication, which treats illnesses associated with rapid heart beats. "Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food& Drug Administration for Propafenone...
9/12/17 - HanAll Biopharma and Harbour BioMed Sign Collaboration and License Agreement to Develop Two Novel Biologic Therapies in Greater China
SEOUL, South Korea, SHANGHAI and CAMBRIDGE, Massachusetts, Sept. 12, 2017/ PRNewswire/ HanAll Biopharma Co., Ltd. and Harbour BioMed announced today that they have entered into a strategic collaboration and license agreement to develop, manufacture and commercialize in Greater China HanAll's two novel biologics, the anti-FcRn monoclonal antibody,
9/12/17 - HEAT BIOLOGICS, INC. FILES (8-K) Disclosing Other Events, Financial Statements and Exhibits
On September 12, 2017, Heat Biologics, Inc. issued a press release announcing that the Company has been granted a Type C meeting with the U.S. Food and Drug Administration to discuss the registrational pathway for its non-small cell lung cancer trial with HS-110 in combination with Bristol Myers-Squibb's Opdivo based upon its maturing Phase 2 da
9/12/17 - Immunotherapy Combination Improves Survival in Advanced Melanoma
The Dana-Farber Cancer Institute issued the following news release:. Patients who received nivolumab either alone or together with ipilimumab, had three-year survival rates of 52 percent and 58 percent, respectively, versus 34 percent with ipilimumab alone, according to researchers from Dana-Farber Cancer Institute, the Royal Marsden Hospital in Lo
9/12/17 - Implanet Announces Clearance of the New JAZZ? Passer
FDA clearance granted in the US for the new system devoted to posterior fixation in spine surgery, compatible with all JAZZ? Platform implants. IMPLANET, a medical technology company specializing in vertebral and knee-surgery implants, today announces that it has received FDA clearance to market the new JAZZ? Passer. Implanet addresses an ever-
9/12/17 - InMed Files Provisional Patent for Biosynthesis of Cannabinoids
-InMed Pharmaceuticals, Inc., a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, today announces the filing of a provisional patent application pertaining to the Company's proprietary biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature
9/12/17 - INNATE PHARMA : New preclinical data further strengthen the rationale of IPH5401 and monalizumab [T-break Tech (Middle East)]
Data were presented at the International Cancer Immunotherapy conference 2017 in Frankfurt. Marseille, France, September 11, 2017, 7:00 A.M. CEST. Innate Pharma SA today announces that new preclinical data for its first-in-class clinical stage antibodies IPH5401 and monalizumab, were presented at the 3rd CRI-CIMT-EATI-AACR International Cancer...
9/12/17 - Innovation Pharmaceuticals Secures New $30 Million Common Stock Purchase Agreement [Sport360]
Innovation Pharmaceuticals Inc.,, a clinical stage biopharmaceutical company, today announces that the Company has entered into a new $30 million common stock purchase agreement with Aspire Capital Fund, LLC. The timing of the purchases will be at the sole discretion of Innovation Pharmaceuticals. We are thrilled to again extend our long-term fundi
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement